Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03702270 · ClinicalTrials.gov registry record · NA
The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 2,052
- Enrollment target
NCT03702270: Completed NA study, sponsored by Vanderbilt University Medical Center.
NCT03702270 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 2,052 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03702270, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,052 participants
- Enrollment target
Study Summary
Currently it is estimated that at least 25 million people in the United States are labeled as penicillin allergic although less than 1.5 million of these are truly allergic. Although combined skin testing and oral challenge is an evidence-based de-labeling strategy the high burden of penicillin allergy labels means these services are available only through specialty allergy practices. There is therefore a need to provide evidence for alternative penicillin de-labeling strategies such as direct oral challenge. Previous studies have utilized quasi-experimental designs. Test dose challenges are currently recommended as a strategy for removal of low risk drug allergies, but the current experience is limited to single arm observational studies and evidence-based strategies for identifying low risk patients are lacking. Our objective is to demonstrate the benefit of providing risk stratification in removing penicillin allergy labels for low risk penicillin allergy patients in a randomized controlled trial.
Primary Outcome
The percentage of patients with low risk penicillin allergy whose labels are removed from the medical chart's allergy section.
Interventions
- OTHER Penicillin Allergic Risk Stratification Best Practice Alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,052 participants |
| Start Date | 2020-11-11 |
| Est. Completion | 2023-05-11 |
| Phase | NA |
What the finished NCT03702270 record still lists
NCT03702270 is an interventional study that assigns participants to a tested intervention. Its 2,052 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher).
The record links to 0 conditions, and to 1 intervention - of which Penicillin Allergic Risk Stratification Best Practice Alert is the first listed.
NCT03702270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03702270 about?
NCT03702270 is a clinical study titled "The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal". Currently it is estimated that at least 25 million people in the United States are labeled as penicillin allergic although less than 1.5 million of these are truly allergic. Although combined skin testing and oral challenge is an evidence-based de-labeling strategy the high burden of penicillin alle...
What is the current status of trial NCT03702270?
This trial is currently completed. It is a NA study. The enrollment target is 2,052 participants. The study started on 2020-11-11. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT03702270?
The interventions under investigation include: Penicillin Allergic Risk Stratification Best Practice Alert (OTHER).
Who is sponsoring clinical trial NCT03702270?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03702270's enrollment target sits among peer trials
2,052 51st of 2000 higher than 1,950 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05050084 · 2,050 participants · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- NCT05688982 · 2,049 participants · NA
MOLAR: Mapping Oral Health and Local Area Resources
- NCT06833476 · 2,044 participants
TTVR STRONG Under Coverage With Evidence Development (CED) Study
- NCT04871542 · 2,062 participants
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI